Is There 25% Downside For Pfizer Stock?
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...
Fiscal Year: January - December
Pfizer Inc. (PFE), listed on the NYSE, has a market capitalization of $. As of Feb 21, 2026, the stock is trading at $26.65 per share, offering investors a clear view of its current market value. Pfizer Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 19.53, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Pfizer Inc. also offers a dividend yield of 6.45%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Pfizer Inc. (PFE) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Pfizer Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Pfizer Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Pfizer Inc. is 0, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Pfizer Inc. (PFE) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Pfizer Inc. (PFE) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Pfizer Inc. (PFE) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Pfizer Inc.. To access the full SS Score, consider upgrading your subscription.
Pfizer Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 19.53. Investors should compare these metrics with industry peers to gauge whether Pfizer Inc. is outperforming or underperforming within its sector.
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and C...
Pfizer Inc. delivered a 17% total return since early November, but I remain cautious. I do not recommend buying PFE stock, as the recent rally is not supported by fundamentals. Valuation analysis and ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial,...
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Pfizer remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. PFE's non-COVID portfolio posted 6% operational growth in 2025, with international market...
Pfizer (PFE) is confronting challenges. Even the most prominent companies are not beyond reach.
Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen...
Pfizer (PFE) remains a 'Hold' due to near-term headwinds, including a $1.5B patent cliff in 2026 and declining Covid-19 revenues. PFE's long-acting GLP-1 obesity program, bolstered by the Metsera acqu...
Pfizer made one thing clear this week: It's officially back in the obesity race.
February's top Large Cap Value (GASV) stocks offer 27.69% to 69.77% net gains by February 2027, based on analyst targets. Fourteen of twenty-nine 'safer' lowest-priced GASV 'dogs' are currently buyabl...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics Li...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting t...
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Pfizer Inc. earns a Buy rating as the market overreacts to Q4's non-cash loss and conservative 2026 guidance, overlooking underlying operational strength. Excluding COVID-19 products, PFE posted 9% Yo...
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
On Tuesday, Pfizer Inc. (NYSE:PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.
Pfizer reported Q4 and FY2025 revenues and EPS above expectations, but core revenues declined due to falling COVID product sales. Despite a 6.5% dividend yield and low valuation multiples, PFE remains...
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products.
On Tuesday, Pfizer Inc. (NYSE: PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.
Pfizer reported fourth-quarter results that beat expectations, offering a steadier earnings picture as the company moves further away from the Covid-driven revenue surge of recent years. While demand ...
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration's policies on pricing and tariffs.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 20.43B | Analyst x5 | |
| 2027 | 18.75B | -8.19% | Analyst x7 |
| 2028 | 16.98B | -9.47% | Analyst x7 |
| 2029 | 16.04B | -5.50% | Analyst x6 |
| 2030 | 15.75B | -1.85% | Analyst x6 |
| 2031 | 15.73B | -0.13% | Est @-0.1% |
| 2032 | 15.83B | 0.68% | Est @0.7% |
| 2033 | 16.03B | 1.24% | Est @1.2% |
| 2034 | 16.27B | 1.53% | Est @1.5% |
| 2035 | 16.56B | 1.78% | Est @1.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 9.84B | 1.00 | 9.84B |
| 2025A | 0.00 | 1.00 | 0.00 |
| 2026E | 20.43B | 1.08 | 18.98B |
| 2027E | 18.75B | 1.16 | 16.19B |
| 2028E | 16.98B | 1.25 | 13.62B |
| 2029E | 16.04B | 1.34 | 11.96B |
| 2030E | 15.75B | 1.44 | 10.91B |
| 2031E | 15.73B | 1.55 | 10.12B |
| 2032E | 15.83B | 1.67 | 9.47B |
| 2033E | 16.03B | 1.80 | 8.91B |
| 2034E | 16.27B | 1.94 | 8.40B |
| 2035E | 16.56B | 2.08 | 7.95B |
| Terminal | 331.66B | 2.08 | 159.15B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.